CN-121971455-A - Application of bufalin in preparation of medicines for treating peripheral nerve adhesion diseases

Abstract

The application provides application of bufalin in preparing a medicament for treating peripheral nerve adhesion diseases, relates to the technical field of biomedicine, proves the treatment effect of the bufalin on the peripheral nerve adhesion diseases, realizes effective treatment on the peripheral nerve adhesion on multiple layers of functional recovery, tissue repair and mechanism regulation, has definite action mechanism, application range and physicochemical properties, provides sufficient experimental basis and research basis for developing medicaments for treating the peripheral nerve adhesion diseases, fills the blank of application of the bufalin in the field of treating the peripheral nerve adhesion diseases, and provides brand-new effective thinking and medicament selection for clinically treating the peripheral nerve adhesion diseases.

Inventors

• LIU XIAOYU
• SUN CHENG

Assignees

• 南通大学

Dates

Publication Date

20260505

Application Date

20260316

Claims (10)

1. 1. Application of bufalin in preparing medicine for treating peripheral nerve adhesion diseases is provided.
2. 2. The use of bufalin in the preparation of a medicament for treating peripheral nerve adhesion disease according to claim 1, wherein the bufalin has a CAS number of 465-21-4 and is a steroid cardiac glycoside extracted from skin secretions of bufadienolide.
3. 3. The use of bufalin in claim 1 for preparing medicine for treating peripheral nerve adhesion diseases, wherein the peripheral nerve adhesion diseases are nerve and muscle adhesion diseases caused by traffic accident, war, earthquake and other accidental wounds, including ischialgia adhesion caused by ischialgia adhesion.
4. 4. The use of bufalin in preparing medicine for treating peripheral nerve adhesion diseases of claim 1, wherein the medicine is used for treating peripheral nerve adhesion diseases by regulating and controlling immune microenvironment at nerve injury, reducing expression of pro-inflammatory factors and promoting remyelination repair of damaged nerve.
5. 5. The use of bufalin in claim 4, wherein the pro-inflammatory factor is one or more of IL1 alpha, TNF-alpha and IL1 beta.
6. 6. A medicament is characterized in that the medicament is used for treating peripheral nerve adhesion diseases, and the medicament comprises bufalin.
7. 7. A pharmaceutical composition according to claim 6, wherein the composition further comprises a pharmaceutically acceptable adjuvant.
8. 8. A pharmaceutical composition according to claim 7, wherein the pharmaceutical composition is an injection and the bufalin is administered at a dose of 100 μg/kg by continuous 7-day injection.
9. 9. A pharmaceutical composition according to claim 6, wherein the pharmaceutical composition is capable of increasing peripheral nerve conduction velocity while improving motor balance and pain sensitivity of the body.
10. 10. The drug for treating peripheral nerve adhesion diseases according to claim 6, wherein the drug can inhibit the expression of ASC and TNFα inflammatory proteins in sciatic nerve tissues and exert an anti-inflammatory effect.

Description

Application of bufalin in preparation of medicines for treating peripheral nerve adhesion diseases Technical Field The application relates to the technical field of biomedicine, in particular to application of bufalin in preparing a medicament for treating peripheral nerve adhesion diseases. Background The peripheral nervous system serves as an important bridge for signal transmission between the central nervous system and peripheral target organs of the body, and plays an irreplaceable role in realizing physiological functions such as motor control, sensory perception and the like. Peripheral nerve adhesion diseases are clinical common post-traumatic complications, are mostly caused by traffic accidents, war, earthquakes and other accidental wounds, and damaged peripheral nerves are easy to adhere to tissues such as peripheral muscles and the like after the wounds, so that nerve impulse transfer disorder is caused, a series of clinical symptoms such as limb movement function damage, paresthesia, pain perception disorder and the like are further caused, limb functions and life quality of patients are seriously influenced, and the peripheral nerve adhesion disease is an important difficult problem in the field of clinical wound repair. Unbalanced immune microenvironment and continuous neuroinflammatory reaction at the nerve injury part are core factors which lead to the formation and development of peripheral nerve adhesion, and if the pathological process cannot be effectively regulated, the repair process of nerve injury can be obviously delayed, and even the degree of nerve adhesion is aggravated. The prior intervention method mainly comprises operation release, conventional anti-inflammatory drug treatment and physical rehabilitation, wherein the operation release has potential risks of secondary adhesion and possibly causes additional damage to damaged nerve tissues, the conventional anti-inflammatory and nutritional nerve drugs mainly comprise symptomatic treatment, the immune microenvironment of nerve injury parts is difficult to regulate and control from the pathogenesis level, the sustained nerve inflammation is inhibited, the repair and regeneration of the damaged nerve tissues cannot be effectively promoted, the physical rehabilitation can only be used as an auxiliary means, the pathological state of the nerve adhesion cannot be reversed, and the effective treatment of the diseases is difficult to realize. In summary, there is no specific therapeutic drug and method for targeting peripheral nerve adhesion diseases, which can effectively inhibit nerve inflammation, promote damaged nerve repair and relieve nerve adhesion state, and there is still a dilemma that the effective therapeutic means is deficient in clinical treatment of the diseases, and there is a need to develop a safe and effective therapeutic scheme to solve the clinical problem. Disclosure of Invention The application aims to solve the technical problem that medicines aiming at peripheral nerve adhesion diseases are lacking in the prior art. The application is realized by the following technical scheme: Application of bufalin in preparing medicine for treating peripheral nerve adhesion diseases is provided. Preferably, the bufalin has CAS number 465-21-4 and is steroid cardiac glycoside extracted from skin secretion of bufadienolide. Preferably, the peripheral nerve adhesion disease is nerve and muscle adhesion disease caused by traffic accident, war, earthquake and other accidental wounds, including ischial nerve adhesion of ischial nerve and muscle adhesion. Preferably, the medicament treats peripheral nerve adhesion diseases by regulating the immune microenvironment at the nerve injury site, reducing the expression of pro-inflammatory factors and promoting the remyelination repair of the damaged nerve. Preferably, the pro-inflammatory factor is one or more of IL1 alpha, TNF-alpha, IL1 beta. The application also provides a medicine for treating peripheral nerve adhesion diseases, which comprises bufalin, wherein the chemical structural formula of the bufalin is as follows: 。 preferably, the medicament further comprises other auxiliary agents which are acceptable in medicine. Preferably, the medicine is injection, the administration dosage of bufalin is 100 mug/kg, and the administration mode of continuous 7-day injection is adopted. Preferably, the agent is capable of increasing peripheral nerve conduction velocity while improving the motor balance ability and pain sensitivity of the body. Preferably, the medicine can inhibit the expression of ASC and TNF alpha inflammatory proteins in sciatic nerve tissues and exert anti-inflammatory effect. The specific verification proves that bufogenin can effectively improve the motion balance capacity and the overall motion capacity of the peripheral nerve adhesion model animal, can obviously improve the conduction rate of peripheral nerves such as sciatic nerves, can also enhance the pain sen